STN 125197 Product Sipuleucel T 

# Part D – Clinical (Pharmacology, Efficacy, Safety,and Statistical) Reviewers

| CTD Module 2 Contents | Present? | If not, justification, action & status |
|---|---|---|
| Overall CTD Table of Contents [2.1] | (Y) N | |
| Introduction to the summary documents (1 page) [2.2] | (Y) N | |
| Clinical overview [2.5] | (Y) N | |
| Clinical summary [2.7] (summary of individual studies; comparison and analyses across studies) | (Y) N | |
| ❑ Biopharmaceutics and associated analytical methods | Y (N) | → Not applicable |
| ❑ Clinical pharmacology [includes immunogenicity] | (Y) N | |
| ❑ Clinical Efficacy [for each indication] | (Y) N | |
| ❑ Clinical Safety | (Y) N | |
| ❑ Synopses of individual studies | (Y) N | |

| CTD Module 5 Contents | Present? | If not, justification, action & status |
|---|---|---|
| Module Table of Contents [5.1] | (Y) N | |
| Tabular Listing of all clinical studies [5.2] | (Y) N | |
| Study Reports and related information [5.3] | (Y) N | |
| ❑ Biopharmaceutic | (Y) N | |
| ❑ Studies pertinent to Pharmacokinetics using Human Biomaterials | Y (N) | → Not applicable |
| ❑ Pharmacokinetics (PK) | Y (N) | } Not applicable |
| ❑ Pharmacodynamic (PD) | Y (N) | |
| ❑ Efficacy and Safety | (Y) N | |
| ❑ Postmarketing experience | Y (N) | → product has not been approved |
| ❑ Case report forms | (Y) N | |
| ❑ Individual patient listings (indexed by study) | (Y) N | |
| ○ electronic datasets (e.g. SAS) | (Y) N | |
| Literature references and copies [5.4] | (Y) N | |

| Examples of Filing Issues | Yes? | If not, action & status |
|---|---|---|
| Content, presentation, and organization sufficient to permit substantive review? | (Y) N | |
| ❑ legible | (Y) N | |
| ❑ English (or certified translation into English) | (Y) N | |
| ❑ compatible file formats | (Y) N | |
| ❑ navigable hyper-links | (Y) N | |
| ❑ interpretable data tabulations (line listings) & graphical displays | (Y) N | |

| Examples of Filing Issues | Yes? | If not, action & status |
|---|---|---|
| ❑ summary reports reference the location of individual data and records<br>❑ protocols for clinical trials present<br>❑ all electronic submission components usable | (Y) N<br>(Y) N<br>(Y) N | |
| statement for each clinical investigation:<br>❑ conducted in compliance with IRB requirements<br>❑ conducted in compliance with requirements for informed consent | (Y) N<br>(Y) N | |
| adequate and well-controlled clinical study data (e.g. not obviously inappropriate or clinically irrelevant study design or endpoints for efficacy) | (Y) N | |
| adequate explanation of why results from what appears to be a single controlled trial (or alternate method for demonstrating efficacy) should be accepted as scientifically valid without replication | (Y) N | |
| study design not clearly inappropriate (as reflected in regulations, well-established agency interpretation or correspondence) for the particular claim | (Y) N | |
| study(ies) assess the contribution of each component of a combination product [21 CFR 610.17] | Y (N) | Not applicable |
| total patient exposure (numbers or duration) at relevant doses is not clearly inadequate to evaluate safety (per standards communicated during IND review, or ICH or other guidance documents) | (Y) N | |
| adequate data to demonstrate safety and/or effectiveness in the population intended for use of the biological product based on age, gender, race, physiologic status, or concomitant therapy | (Y) N | |
| drug interaction studies communicated as during IND review as necessary are included | Y (N) | Not applicable |
| assessed drug effects whose assessment is required by well established agency interpretation or communicated during IND review | (Y) N | |
| comprehensive analysis of safety data from all current world-wide knowledge of product | (Y) N | |

STN 125197 Product Sipuleucel T 

| Examples of Filing Issues | Yes? | If not, action & status |
|---|---|---|
| data supporting the proposed dose and dose interval | (Y) N | |
| appropriate (e.g. protocol-specified) and complete statistical analyses of efficacy data | (Y) N | |
| adequate characterization of product specificity or mode of action | Y N | |
| data demonstrating comparability of product to be marketed to that used in clinical trials when significant changes in manufacturing processes or facilities have occurred | Y (N) | Not applicable |
| inadequate efficacy and/or safety data on product to be marketed when different from product used in clinical studies which are the basis of safety and efficacy determinations | Y (N) | Not applicable |
| all information reasonably known to the applicant and relevant to the safety and efficacy described? | (Y) N | |

| List of Clinical Studies (protocol number) | Final study report submitted? | Financial disclosure or certification submitted? | SAS & other electonic datasets complete & usable? | BiMo sites identified? |
|---|---|---|---|---|
| D9901 | (Y) N | (Y) N NR | (Y) N | (Y) N NR |
| D9902A | (Y) N | (Y) N NR | (Y) N | (Y) N NR |
| | Y N | Y N NR | Y N | Y N NR |
| | Y N | Y N NR | Y N | Y N NR |
| | Y N | Y N NR | Y N | Y N NR |
| | Y N | Y N NR | Y N | Y N NR |
| | Y N | Y N NR | Y N | Y N NR |
| | Y N | Y N NR | Y N | Y N NR |
| | Y N | Y N NR | Y N | Y N NR |
| | Y N | Y N NR | Y N | Y N NR |

Y= yes; N=no; NR=not required

STN 125197 Product Sipuleucel T 

List any issue not addressed above which should be identified as a reason for not filing the BLA/BLS. Also provide additional details if above charts did not provide enough room (or attach separate memo).

none

Is clinical site(s) inspection (BiMo) needed?

Yes.

Is an Advisory Committee needed?

Yes.

Recommendation (circle one): File RTF

Reviewer: [signature] 12-18-06 Type (circle one): Clinical Clin/Pharm Statistical
(signature/ date)

Ke Liu, MD PhD

Concurrence:

Branch Chief: _____ Division. Director: _____
(signature/ date) (signature/ date)